Ver­tex dos­es first pa­tient with next type 1 di­a­betes cell ther­a­py pro­gram, while padding its cof­fers with strong Q2

Ver­tex has dosed the first type 1 di­a­betes pa­tient with its next cell ther­a­py pro­gram, the Boston biotech said Tues­day as part of its quar­ter­ly earn­ings up­date.

Ver­tex’s first cell ther­a­py pro­gram, VX-880, has im­pressed with ear­ly clin­i­cal re­sults, show­ing a one-time in­fu­sion of these in­sulin-pro­duc­ing cells brought sig­nif­i­cant ef­fects in the first hand­ful of treat­ed pa­tients. Those re­sults, pre­sent­ed at June’s Amer­i­can Di­a­betes As­so­ci­a­tion an­nu­al con­fer­ence, in­clud­ed two treat­ed pa­tients with over a year of fol­low-up who have re­mained free from us­ing in­sulin with no se­vere hy­po­glycemic events.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.